Prognostic factors for intravitreal conbercept in the treatment of choroidal neovascularization secondary to pathological myopia.
Humans
Choroidal Neovascularization
/ drug therapy
Intravitreal Injections
Male
Myopia, Degenerative
/ complications
Female
Recombinant Fusion Proteins
/ administration & dosage
Middle Aged
Visual Acuity
Prognosis
Tomography, Optical Coherence
/ methods
Fluorescein Angiography
/ methods
Retrospective Studies
Follow-Up Studies
Adult
Aged
Treatment Outcome
Angiogenesis Inhibitors
/ administration & dosage
Fundus Oculi
Choroidal neovascularization
Conbercept
Optical coherence tomography angiography
Pathological myopia
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
22 Jun 2024
22 Jun 2024
Historique:
received:
12
01
2024
accepted:
15
06
2024
medline:
22
6
2024
pubmed:
22
6
2024
entrez:
22
6
2024
Statut:
epublish
Résumé
To identify risk factors influencing visual outcomes in patients with pathological myopia-associated choroidal neovascularization (PM-CNV) following intravitreal injections of conbercept. A total of 86 eyes from 86 patients received intravitreal conbercept in a 1 + PRN regimen. After the initial injection, patients were followed for 12 months. They were categorized into two groups based on their 12-month visual acuity change: those who achieved greater than a one-line improvement in BCVA (improved group; n = 65) and those who experienced a one-line or lesser improvement or a decrease in BCVA (non-improved group; n = 21). Over the 12-month period, the mean BCVA in the improved group significantly improved from 0.82 to 0.41 LogMAR. In the non-improved group, BCVA changed from 1.24 to 1.09 LogMAR. Similarly, the mean CRT decreased from 426.21 μm at baseline to 251.56 μm at 12 months in the improved group, and from 452.47 to 382.45 μm in the non-improved group. Multivariable logistic regression analyses revealed that older age (OR 1.287; 95% CI 1.019-1.625; P = 0.034), poorer baseline BCVA (OR 6.422; 95% CI 1.625-25.384; P = 0.008), the presence of subfoveal CNV (OR 4.817; 95% CI 1.242-18.681; P = 0.023), and organized interlacing patterns of CNV morphology (OR 5.593; 95% CI 1.397-22.392; P = 0.015) emerged as independent risk factors correlated with worsened visual prognosis following intravitreal conbercept injections. Conbercept demonstrates significant efficacy and safety in treating PM-CNV. Key factors influencing visual recovery post-treatment include older age, poorer baseline BCVA, the presence of subfoveal CNV, and organized interlacing patterns of CNV morphology.
Identifiants
pubmed: 38907787
doi: 10.1007/s10792-024-03177-8
pii: 10.1007/s10792-024-03177-8
doi:
Substances chimiques
KH902 fusion protein
1P05PW62F3
Recombinant Fusion Proteins
0
Angiogenesis Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
253Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Baird PN, Saw SM, Lanca C et al (2020) Myopia. Nat Rev Dis Prim 6(1):99
doi: 10.1038/s41572-020-00231-4
pubmed: 33328468
Wolffsohn JS, Flitcroft DI, Gifford KL et al (2019) IMI–myopia control reports overview and introduction. Invest Ophthalmol Vis Sci 60(3):M1–M19
doi: 10.1167/iovs.18-25980
pubmed: 30817825
pmcid: 6735780
Adatia FA, Luong M, Munro M, Tufail A (2015) The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents. Surv Ophthalmol 60(3):204–215
doi: 10.1016/j.survophthal.2014.10.002
pubmed: 25890624
Chan NS-W, Teo K, Cheung CMG (2016) Epidemiology and diagnosis of myopic choroidal neovascularization in Asia. Eye Contact Lens 42(1):48–55
doi: 10.1097/ICL.0000000000000201
pubmed: 26448447
Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92–106
doi: 10.1016/j.preteyeres.2017.10.005
pubmed: 29111299
Fang Y, Yokoi T, Nagaoka N et al (2018) Progression of myopic maculopathy during 18-year follow-up. Ophthalmology 125(6):863–877
doi: 10.1016/j.ophtha.2017.12.005
pubmed: 29371011
Hayashi K, Ohno-Matsui K, Shimada N et al (2010) Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmology 117(8):1595–611.e1-4
doi: 10.1016/j.ophtha.2009.11.003
pubmed: 20207005
Toto L, Di Antonio L, Costantino O, Mastropasqua R (2021) Anti-VEGF therapy in myopic CNV. Curr Drug Targets 22(9):1054–1063
doi: 10.2174/1389450122999210128180725
pubmed: 33511955
Zhu Y, Zhang T, Xu G, Peng L (2016) Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 12(12):Cd011160
pubmed: 27977064
Teo KYC, Ng WY, Lee SY, Cheung CMG (2016) Management of myopic choroidal neovascularization: focus on anti-VEGF therapy. Drugs 76(11):1119–1133
doi: 10.1007/s40265-016-0605-0
pubmed: 27364753
Cheung CMG, Arnold JJ, Holz FG et al (2017) Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 124(11):1690–1711
doi: 10.1016/j.ophtha.2017.04.028
pubmed: 28655539
Liu H, Ma Y, Xu HC, Huang LY, Zhai LY, Zhang XR (2020) Updates on the management of ocular vasculopathies with VEGF inhibitor conbercept. Curr Eye Res 45(12):1467–1476
doi: 10.1080/02713683.2020.1781193
pubmed: 32631094
Ng DSC, Fung NSK, Yip FLT, Lai TYY (2020) Ranibizumab for myopic choroidal neovascularization. Expert Opin Biol Ther 20(12):1385–1393
doi: 10.1080/14712598.2021.1830969
pubmed: 33003962
Cohen SY, Nghiem-Buffet S, Grenet T et al (2015) Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab. Jpn J Ophthalmol 59(1):36–42
doi: 10.1007/s10384-014-0363-z
pubmed: 25416566
Onishi Y, Yokoi T, Kasahara K et al (2019) Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia. Retina 39(7):1289–1298
doi: 10.1097/IAE.0000000000002164
pubmed: 29746414
Sayanagi K, Uematsu S, Hara C et al (2019) Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 257(4):749–757
doi: 10.1007/s00417-018-04214-w
pubmed: 30643966
Bae KW, Kim DI, Kim BH et al (2022) Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment. PLoS ONE 17(9):e0273613
doi: 10.1371/journal.pone.0273613
pubmed: 36137056
pmcid: 9499232
Ng DS, Kwok AK, Tong JM, Chan CW, Li WW (2015) Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization. Retina 35(12):2457–2468
doi: 10.1097/IAE.0000000000000610
pubmed: 26035400
Sarao V, Veritti D, Macor S, Lanzetta P (2016) Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes. Graefes Arch Clin Exp Ophthalmol 254(3):445–454
doi: 10.1007/s00417-015-3076-1
pubmed: 26084446
Woronkowicz M, Hamilton R, Lightman S, Zagora S, Tomkins-Netzer O (2023) Comparison of anatomical and functional outcomes of treating myopic choroidal neovascularization with bevacizumab or ranibizumab. Int Ophthalmol 43:3499–3507
doi: 10.1007/s10792-023-02755-6
pubmed: 37318668
Bruyère E, Miere A, Cohen SY et al (2017) Neovascularization secondary to high myopia imaged by optical coherence tomography angiography. Retina 37(11):2095–2101
doi: 10.1097/IAE.0000000000001456
pubmed: 28590317
Nakano Y, Kataoka K, Takeuchi J et al (2019) Vascular maturity of type 1 and type 2 choroidal neovascularization evaluated by optical coherence tomography angiography. PLoS ONE 14(4):e0216304
doi: 10.1371/journal.pone.0216304
pubmed: 31034505
pmcid: 6488195
Nie X, Wang Y, Yi H, Qiao Y (2021) Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China: intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol 21(1):116
doi: 10.1186/s12886-021-01877-8
pubmed: 33663431
pmcid: 7934258
Anguita R, Tasiopoulou A, Shahid S, Roth J, Sim SY, Patel PJ (2021) A review of aflibercept treatment for macular disease. Ophthalmol Ther 10(3):413–428
doi: 10.1007/s40123-021-00354-1
pubmed: 34120317
pmcid: 8319283
Zhu W, Hao Y, Yuan Z, Huang C (2023) High-dose aflibercept injection has striking effects on myopic choroidal neovascularization. Exp Ther Med 25(6):301
doi: 10.3892/etm.2023.12000
pubmed: 37229317
pmcid: 10203910
Wang HY, Tao MZ, Wang XX et al (2021) Baseline characteristics of myopic choroidal neovascularization in patients above 50 years old and prognostic factors after intravitreal conbercept treatment. Sci Rep 11(1):7337
doi: 10.1038/s41598-021-86835-6
pubmed: 33795797
pmcid: 8016885
Mallone F, Giustolisi R, Franzone F et al (2021) Ten-year outcomes of intravitreal bevacizumab for myopic choroidal neovascularization: analysis of prognostic factors. Pharmaceuticals (Basel) 14(10):1042
doi: 10.3390/ph14101042
pubmed: 34681267
Ravenstijn M, Klaver CCW, Yzer S (2023) Long-term treatment outcomes after bevacizumab therapy for macular neovascularization in White patients with high myopia. Retina 43(3):444–453
doi: 10.1097/IAE.0000000000003675
pubmed: 36395427
Batıoğlu F, Yanık Ö, Demirel S, Özmert E (2023) Clinical use of optical coherence tomography angiography in retinal diseases. Diagnostics (Basel) 13(10):1820
doi: 10.3390/diagnostics13101820
pubmed: 37238303
Ramakrishnan T, Chandra S, Sivaprasad S (2021) Long-term follow-up of management of choroidal neovascularisation secondary to angioid streaks with intravitreal anti-vascular endothelial growth factor. Eye (Lond) 35(3):853–857
doi: 10.1038/s41433-020-0979-9
pubmed: 32461565
Lu H, Yue T, Liu N et al (2021) Efficacy of Conbercept in the treatment of choroidal neovascularization secondary to pathologic myopia. Front Med 8:720804
doi: 10.3389/fmed.2021.720804
Yan M, Huang Z, Lian HY, Song YP, Chen X (2019) Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol 97(5):e813–e814
doi: 10.1111/aos.13632
pubmed: 30187680
Javed A, Khanna A, Palmer E et al (2023) Optical coherence tomography angiography: a review of the current literature. J Int Med Res 51(7):3000605231187933
doi: 10.1177/03000605231187933
pubmed: 37498178
Song L, Luo C, Zheng Y, Sha X (2023) Clinical outcomes of different regimens of intravitreal Conbercept for the treatment of choroidal neovascularization secondary to pathological myopia. Int Ophthalmol 43(10):3445–3452
doi: 10.1007/s10792-023-02655-9
pubmed: 37561252
Liu K, Song Y, Xu G et al (2019) Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol 197:156–167
doi: 10.1016/j.ajo.2018.08.026
pubmed: 30148987
Zhou P, Zheng S, Wang E, Men P, Zhai S (2021) Conbercept for treatment of neovascular age-related macular degeneration and visual impairment due to diabetic macular edema or pathologic myopia choroidal neovascularization: a systematic review and meta-analysis. Front Pharmacol 12:696201
doi: 10.3389/fphar.2021.696201
pubmed: 34712132
pmcid: 8546330
Xia JP, Liu SQ, Wang S (2021) Intravitreal conbercept improves outcome of proliferative diabetic retinopathy through inhibiting inflammation and oxidative stress. Life Sci 265:118795
doi: 10.1016/j.lfs.2020.118795
pubmed: 33227274
Ferrara D (2016) Image artifacts in optical coherence tomography angiography. Clin Exp Ophthalmol 44(5):367–368
doi: 10.1111/ceo.12781
pubmed: 27381573